诊断学理论与实践

诊断学理论与实践 >

2026 , Vol. 25 >Issue 03: 354 - 360

DOI: https://doi.org/10.16150/j.1671-2870.2026.03.012

论著

抗中性粒细胞胞浆抗体相关性肾小球肾炎患者中血清可溶性CD206与疾病活动度间相关性

  • 魏兆楠 ,
  • 安晓宁 ,
  • 倪莉燕 ,
  • 沈平雁 ,
  • 史浩 ,
  • 张文 ,
  • 陈永熙
展开
  • 1 上海交通大学医学院附属瑞金医院肾脏科， 上海 200025
    2 苏州大学附属第二医院肾内科， 苏州 215004
作者贡献/Authors’ Contributions

魏兆楠，安晓宁负责实验研究、数据分析，魏兆楠负责文章撰写，倪莉燕负责ANCA以及临床标本检验，沈平雁、史浩和张文负责临床标本收集，陈永熙负责数据核对以及文章审核。

陈永熙 E-mail： rickychen@sjtu.edu.cn

收稿日期: 2025-09-07

  修回日期: 2025-12-02

  录用日期: 2025-12-03

  网络出版日期: 2026-06-27

基金资助

国家自然科学基金(81000285);国家自然科学基金(81470041);国家自然科学基金重点国际（地区）合作研究项目(82120108007);国家转化医学研究中心（上海）开放课题(TMSK-2024-101);国家转化医学研究中心（上海）开放课题(NRCTM（SH）-2025-10（瑞金基地）)

收起

Correlation between serum soluble CD206 and disease activity in patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis

  • WEI Zhaonan ,
  • AN Xiaoning ,
  • NI Liyan ,
  • SHEN Pingyan ,
  • SHI Hao ,
  • ZHANG Wen ,
  • CHEN Yongxi
Expand
  • 1 Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2 Department of Nephrology, Second Affiliated Hospital, Soochow University, Suzhou 215004, China

Received date: 2025-09-07

  Revised date: 2025-12-02

  Accepted date: 2025-12-03

  Online published: 2026-06-27

Fold

摘要

目的：探究血清可溶性CD206（serum soluble CD206， sCD206）水平在抗中性粒细胞胞浆抗体（anti-neutrophil cytoplasmic antibodies， ANCA）相关性肾小球肾炎（ANCA associated glomerulonephritis， AGN）患者中的表达特征，及其对疾病活动度的评估价值。方法：连续招募2020年1月至2022年12月期间于上海交通大学医院附属瑞金医院肾脏科住院治疗的54例AGN患者，所有患者均符合Chapel Hill Consensus Conference 2012诊断标准。AGN患者住院期间，共收集活动期AGN患者血清标本38例、缓解期AGN患者血清标本29例，其中13例患者同时提供了活动期和缓解期标本。另招募14名年龄、性别匹配的健康志愿者作为对照。采用双抗体夹心酶联免疫吸附试验（enzyme linked immunosorbent assay， ELISA）测定所有研究对象的血清sCD206水平，比较健康志愿者、活动期AGN患者与缓解期AGN患者3组间的差异，并对13例在研究期间达到临床缓解的活动期患者，进行其活动期与缓解期标本的配对分析。分析血清sCD206水平与AGN相关临床指标[血清肌酐、估算肾小球滤过率（estimated glomerular filtration rate， eGFR）、24 h尿蛋白、伯明翰血管炎活动性评分（Birmingham vasculitis activity score，BVAS）、红细胞沉降率等]之间的相关性，并通过受试者操作特征（receiver operator characteristic， ROC）曲线分析血清sCD206水平评估AGN疾病缓解的效能。结果：活动期AGN患者的sCD206水平[（2.359±0.827） AU]显著高于缓解期患者[（0.989±0.230） AU]及健康对照者[（1.074±0.528） AU]（P均<0.000 1），同一患者缓解期的血清sCD206水平较活动期显著下降（ΔsCD206=1.439±0.873，P<0.01），而缓解期AGN患者的血清sCD206水平与健康对照者间没有差异（P>0.05）。血清sCD206水平与临床指标间的相关性分析结果显示，活动期AGN患者的血清sCD206水平与BVAS呈显著正相关（r=0.577，P<0.001）。ROC曲线分析显示，血清sCD206水平预测AGN患者临床缓解的曲线下面积为0.876，最佳临界值为1.547 AU，此时的灵敏度为86.21%，特异度为78.95%。结论：AGN患者的血清sCD206水平随疾病活动度下降而显著降低，可作为评估AGN患者临床缓解的潜在标志物。

关键词： 可溶性CD206; 抗中性粒细胞包浆抗体; 肾小球肾炎

本文引用格式

魏兆楠 , 安晓宁 , 倪莉燕 , 沈平雁 , 史浩 , 张文 , 陈永熙 . 抗中性粒细胞胞浆抗体相关性肾小球肾炎患者中血清可溶性CD206与疾病活动度间相关性[J]. 诊断学理论与实践, 2026 , 25(03) : 354 -360 . DOI: 10.16150/j.1671-2870.2026.03.012

Abstract

Objective This study aims to investigate the expression characteristics of serum soluble CD206 (sCD206) in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis (AGN) and its value in assessing disease activity. Methods A total of 54 AGN patients hospitalized in the Department of Nephrology of Ruijin Hospital from January 2020 to December 2022 were consecutively enrolled, and 38 active-phase serum specimens and 29 remission-phase specimens for each were collected. Among them, 13 patients provided both active-phase and remission-phase serum specimens. Additionally, 14 age- and sex-matched healthy volunteers were recruited as controls. Serum sCD206 levels of all subjects were measured using double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Comparisons were made among healthy controls, active-phase AGN patients, and remission-phase AGN patients. Paired analysis was performed on active-phase and remission-phase specimens from the 13 patients who achieved clinical remission during the study period. Correlations between serum sCD206 levels and AGN-related clinical indicators [serum creatinine, estimated glomerular filtration rate (eGFR), 24-hour urinary protein, Birmingham Vasculitis Activity Score (BVAS), erythrocyte sedimentation rate, etc.] were analyzed. The efficacy of serum sCD206 levels on assessing disease remission in AGN was evaluated using receiver operating characteristic (ROC) curve. Results Serum sCD206 levels in active-phase AGN patients [(2.359±0.827) AU] were significantly higher than those in remission-phase patients [(0.989±0.230) AU] and healthy controls [(1.074±0.528) AU] (all P<0.000 1). The serum sCD206 levels of the same patients during the remission phase were significantly lower than those during the active phase (ΔsCD206=1.439±0.873 AU, P<0.01). There was no significant difference in serum sCD206 levels between remission-phase AGN patients and healthy controls (P>0.05). Correlation analysis showed that serum sCD206 levels in active-phase AGN patients were positively correlated with BVAS (r=0.577, P<0.001). ROC curve analysis showed that the area under the curve (AUC) of serum sCD206 levels for assessing clinical remission in AGN patients was 0.876. The optimal cutoff value was 1.547 AU, with a sensitivity of 86.21% and a specificity of 78.95%. Conclusions Serum sCD206 levels decrease significantly as disease activity declines, and can serve as a potential biomarker for evaluating clinical remission in AGN patients.

Key words： Soluble CD206; Anti-neutrophil cytoplasmic antibodies; Glomerulonephritis

参考文献

[1] JENNETTE J C, FALK R J, BACON P A, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides[J]. Arthritis Rheum,2013, 65(1):1-11.
[2] SACHEZ-ALAMO B, MOI L, BAJEMA I, et al. Long-term outcome of kidney function in patients with ANCA-associated vasculitis[J]. Nephrol Dial Transplant, 2024, 39(9):1483-1493.
[3] CHEN Y X, CHEN X N. Antineutrophil cytoplasmic antibodies-associated glomerulonephritis: From bench to bedside[J]. Chronic Dis Transl Med, 2018, 4(3):187-191.
[4] VEGTING Y, VOGT L, ANDERS H J, et al. Monocytes and macrophages in ANCA-associated vasculitis[J]. Autoimmun Rev, 2021, 20(10):102911.
[5] AN X N, WEI Z N, XIE Y Y, et al. CD206+CD68+ mono-macrophages and serum soluble CD206 level are increased in antineutrophil cytoplasmic antibodies associa-ted glomerulonephritis[J]. BMC Immunol, 2022, 23(1):55.
[6] VAN DER ZANDE H J P, NITSCHE D, SCHLAUTMANN L, et al. The mannose receptor: From endocytic receptor and biomarker to regulator of (meta)inflammation[J]. Front Immunol, 2021,12:765034.
[7] MARTíNEZ-POMARES L, MAHONEY J A, KáPOSZTA R, et al. A functional soluble form of the murine mannose receptor is produced by macrophages in vitro and is present in mouse serum[J]. J Biol Chem, 1998, 273(36):23376-23380.
[8] 吴彩, 许俊, 彭红英, 等. 中性粒细胞胞外诱捕网在慢性肾脏病发生发展中的作用[J]. 中国临床研究, 2025, 38 (9): 1310-1313,1318.
  WU C, XU J, PENG H Y, et al. Role of neutrophil extracellular traps in the development and progression of chronic kidney disease[J]. Chin J Clin Res, 2025, 38 (9): 1310-1313,1318.
[9] AN X N, WEI Z N, YAO X Y, et al. Evaluating renal outcome of ANCA-associated renal vasculitis: Comparative study of two histopathological scoring systems[J]. Clin Exp Rheumatol, 2021, 39 Suppl 129(2):39-45.
[10] CHEN Y X, XU J, PAN X X, et al. Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: A study of 186 patients and metaanalysis[J]. J Rheumatol, 2017, 44(3):304-313.
[11] CHEN Y X, ZHANG W, CHEN X N, et al. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis[J]. Clin Exp Rheumatol, 2014, 32(3Suppl 82): S5-S10.
[12] CHEN Y X, ZHANG W, CHEN X N, et al. Application of RIFLE criteria in Chinese patients with ANCA-associated renal vasculitis[J]. Clin Exp Rheumatol, 2011, 29(6):951-957.
[13] GULATI K, EDWARDS H, PRENDECKI M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis[J]. Kidney Int, 2021, 100(6):1316-1324.
[14] BOOTH A D, ALMOND M K, BURNS A, et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study[J]. Am J Kidney Dis, 2003, 41(4):776-784.
[15] WALLACE Z S, FU X, HARKNESS T, et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type[J]. Rheumatology, 2020, 59(9):2308-2315.
[16] MARIE RELSTER M, GAINI S, M?LLER H J, et al. The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious di-sease with or without sepsis[J]. Scand J Clin Lab Invest, 2018, 78(3):180-186.
[17] ZOU R, GUI X, ZHANG J, et al. Association of serum macrophage-mannose receptor CD206 with mortality in idiopathic pulmonary fibrosis[J]. Int Immunopharmacol, 2020,86:106732.
[18] SHEN Y W, ZHANG Y M, HUANG Z G, et al. Increased levels of soluble CD206 associated with rapidly progressive interstitial lung disease in patients with dermatomyositis[J]. Mediators Inflamm, 2020,2020:7948095.
[19] HEFTDAL L D, STENGAARD-PEDERSEN K, ?RNBJERG L M, et al. Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity[J]. Scand J Clin Lab Invest, 2017, 77(5):385-389.
[20] HEFTDAL L D, LOFT A G, HENDRICKS O, et al. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis[J]. Scand J Clin Lab Invest, 2018, 78(6):483-489.
[21] WEI Z, AN X, XIE Y, et al. NLRP3 inflammasome acti-vity and pyroptosis are involved in CD206+ macrophage activation by MPO anti-neutrophil cytoplasmic antibodies[J]. Acta Biochim Biophys Sin (Shanghai), 2025, 57(11):1791-1802.
[22] TOMASSON G, GRAYSON P C, MAHR A D, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis: A meta-analysis[J]. Rheumatology (Oxford), 2012, 51(1):100-109.
[23] AENDEKERK J P, JIEMY W F, RAVELING-EELSING E, et al. CD163 and CD206 expression define distinct macrophage subsets involved in active ANCA-associated glomerulonephritis[J]. J Autoimmun, 2022,133:102914.
Options
文章导航

/

〈 〉